Amivantamab with carboplatin and pemetrexed [AMI2]

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced, non- squamous, non-small-cell lung cancer where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy with amivantamab with chemotherapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has a histologically or cytologically documented non-small cell lung cancer (NSCLC) that has been shown to exhibit an epidermal growth factor (EGFR) exon 20 insertion mutation OR there is documented agreement by the lung MDT that the radiological appearances are in keeping with recurrent/locally advanced/metastatic NSCLC AND there is an informative circulating free DNA test result confirming the presence of an EGFR exon 20 insertion mutation. Please mark below on which basis the diagnosis of EGFR mutation positive NSCLC has been made in this patient:

• Histological or cytological evidence and tissue/ctDNA testing, or
• Documented agreement by the lung MDT that the radiological appearances are in keeping with locally advanced or metastatic NSCLC and there is an informative circulating free DNA test result confirming the presence of an EGFR exon 20 insertion mutation

3. The patient has locally advanced or metastatic disease, and that for this disease indication, the patient has not received any previous systemic anti-cancer therapy.
4. The patient has an ECOG performance status (PS) of 0 or 1.
5. The patient will be treated with amivantamab in combination with pemetrexed and carboplatin for an initial 4 x 3-weekly cycles, followed by pemetrexed in combination with amivantamab until loss of clinical benefit, or excessive toxicity, or patient choice to discontinue treatment, whichever is the sooner. If a patient experiences severe toxicity specifically related to pemetrexed, amivantamab can be continued as a single agent.
6. The patient will be treated with the intravenous formulation of amivantamab. (Note – the subcutaneous formulation is NOT currently licensed in the UK for this indication)
7. Where a treatment break of more than 6 weeks beyond the expected 3-weekly cycle length is needed, a treatment break approval form will be completed to restart treatment, which MUST be approved before treatment is recommenced.
8. Amivantamab will otherwise be used as set out in its Summary of Product Characteristics (SPC).

CDF funded From: 08 May 2026

Additional information

Form version: -

CDF Managed Access: Yes

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.397 of the CDF list, downloaded from NHS England’s website on 15 May 2026 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.